Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Phase 2

Terminated

Conditions: Refractory Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-02-02

Last Posted Date: 2015-03-09

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 3

Registration Number: NCT02353468

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-01-28

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 65

Registration Number: NCT02348528

Locations: 🇨🇳
Xiangya Hospital of Central South University, Changsha, China
🇨🇳
1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, China
🇨🇳
Shanghai Changzheng Hospital, Shanghai, China

and more 7 locations

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Bortezomib
Drug: Lenalidomide
Drug: Daratumumab
Drug: Carfilzomib
Drug: Ixazomib
Drug: Belantamab Mafodotin
Drug: Mezigdomide
Drug: Elotuzumab
Drug: Clarithromycin

First Posted Date: 2015-01-21

Last Posted Date: 2024-05-07

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 300

Registration Number: NCT02343042

Locations: 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

and more 21 locations

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Phase 1

Completed

Conditions: T-cell Lymphomas
Relapsed or Refractory

Interventions: Drug: Carfilzomib
Drug: Romidepsin
Drug: Lenalidomide

First Posted Date: 2015-01-19

Last Posted Date: 2024-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT02341014

Locations: 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 3 locations

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-01-12

Last Posted Date: 2020-11-06

Lead Sponsor: Amgen

Target Recruit Count: 107

Registration Number: NCT02335983

Locations: 🇺🇸
Saint Francis Hospital Cancer Center, Greenville, South Carolina, United States
🇺🇸
Greenville Health System, Greenville, South Carolina, United States
🇺🇸
Morton Coleman, MD, New York, New York, United States

and more 27 locations

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Phase 1

Active, not recruiting

Conditions: Partial Response of Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell Myeloma

Interventions: Biological: Incomplete Freund's Adjuvant
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Sargramostim
Biological: SVN53-67/M57-KLH Peptide Vaccine

First Posted Date: 2015-01-08

Last Posted Date: 2024-06-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT02334865

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Autologous Stem Cell Transplant
Drug: Melphalan
Drug: Lenalidomide
Drug: MK-3475

First Posted Date: 2015-01-06

Last Posted Date: 2018-07-27

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 32

Registration Number: NCT02331368

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2014-12-23

Last Posted Date: 2020-05-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 273

Registration Number: NCT02322320

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
BMT Group of Georgia (Northside Hospital), Atlanta, Georgia, United States

and more 39 locations

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Phase 1

Active, not recruiting

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: Lenalidomide
Drug: Velcade

First Posted Date: 2014-12-09

Last Posted Date: 2024-03-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 22

Registration Number: NCT02312102

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

Phase 2

Terminated

Conditions: Stage 0 Chronic Lymphocytic Leukemia
Monoclonal B-Cell Lymphocytosis
Stage I Small Lymphocytic Lymphoma
Stage I Chronic Lymphocytic Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Pneumococcal 13-valent Conjugate Vaccine

First Posted Date: 2014-12-05

Last Posted Date: 2021-01-19

Lead Sponsor: Mayo Clinic

Target Recruit Count: 12

Registration Number: NCT02309515

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy